PRKCD and Alzheimer disease: Importantly, in a transgenic AD mouse model, inhibition of PKCδ by rottlerin has been shown to markedly reduce the expression of β-site APP-cleaving enzyme I (BACE1, a novel aspartyl protease in Aβ genesis), Aβ levels, and plaque formation and improves cognitive deficits (Du et al., 2018).